Matching articles for "Lopressor"
Issue 1703 · May 27, 2024
Drugs for Hypertension

American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed…

Med Lett Drugs Ther. 2024 May 27; 66(1703):81-8 doi:10.58347/tml.2024.1703a
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1693 · January 8, 2024
Treatment of Atrial Fibrillation

Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of…

Med Lett Drugs Ther. 2024 Jan 8; 66(1693):1-8 doi:10.58347/tml.2024.1693a
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Issue 1678 · June 12, 2023
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

View the Comparison Table: Some Drugs for Migraine Prevention in Adults

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):e100-2 doi:10.58347/tml.2023.1678c
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Issue 1678 · June 12, 2023 Free
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):89-96 doi:10.58347/tml.2023.1678a
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1636 · November 1, 2021
Atogepant (Qulipta) for Migraine Prevention

Atogepant ( Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is…

Med Lett Drugs Ther. 2021 Nov 1; 63(1636):169-71
Atogepant ( Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT) , which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Issue 1608 · October 5, 2020
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2020 Oct 5; 62(1608):153-60
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1599 · June 1, 2020
Eptinezumab (Vyepti) for Migraine Prevention

The FDA has approved eptinezumab-jjmr ( Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth…

Med Lett Drugs Ther. 2020 Jun 1; 62(1599):85-7
The FDA has approved eptinezumab-jjmr ( Vyepti – Lundbeck), a calcitonin gene-related peptide (CGRP) antagonist administered IV once every 3 months, for migraine prevention in adults. It is the fourth monoclonal antibody to be approved for this indication; erenumab ( Aimovig) , fremanezumab (Ajovy) , and galcanezumab ( Emgality) , which are all given subcutaneously once monthly (fremanezumab can also be given once every 3 months), were approved earlier.
Issue 1598 · May 18, 2020
Drugs for Hypertension

Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2020 May 18; 62(1598):73-80
Drugs available for treatment of chronic hypertension and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1580 · September 9, 2019
Drugs for Atrial Fibrillation

Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.

Med Lett Drugs Ther. 2019 Sep 9; 61(1580):137-44
Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated.
Issue 1559 · November 5, 2018
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention

The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm ( Ajovy – Teva) and galcanezumab-gnlm ( Emgality – Lilly), for migraine prevention in…

Med Lett Drugs Ther. 2018 Nov 5; 60(1559):177-80
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm ( Ajovy – Teva) and galcanezumab-gnlm ( Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig) , which targets the CGRP receptor, was the first.
Issue 1549 · June 18, 2018
Erenumab (Aimovig) for Migraine Prevention

The FDA has approved erenumab-aooe ( Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):101-3
The FDA has approved erenumab-aooe ( Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of migraine in adults. It is the first drug in its class to be approved by the FDA.
Issue 1516 · March 13, 2017
Drugs for Hypertension

in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.

Med Lett Drugs Ther. 2017 Mar 13; 59(1516):41-8
in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
Issue 1514 · February 13, 2017
Drugs for Migraine

An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of…

Med Lett Drugs Ther. 2017 Feb 13; 59(1514):27-32
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates.
Issue 1514 · February 13, 2017
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

View the Comparison Table: Some Drugs for Migraine Prevention in Adults

Med Lett Drugs Ther. 2017 Feb 13; 59(1514):e31-2
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Issue 1503 · September 12, 2016
Byvalson - A Beta Blocker/ARB Combination for Hypertension

The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan ( Diovan , and generics), for treatment of…

Med Lett Drugs Ther. 2016 Sep 12; 58(1503):115-7
The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan ( Diovan , and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.
Issue 1446 · July 7, 2014
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.

Med Lett Drugs Ther. 2014 Jul 7; 56(1446):53-8
The treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. New US guidelines for the management of atrial fibrillation have recently been published.
Issue 113 · January 1, 2012
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for…

Treat Guidel Med Lett. 2012 Jan; 10(113):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages and adverse effects, are listed in the tables that begin on page 2. Combination products are listed on page 8. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed previously.
Issue 102 · February 1, 2011
Drugs for Migraine

Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of…

Treat Guidel Med Lett. 2011 Feb; 9(102):7-12
Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 97 · September 1, 2010
Treatment of Atrial Fibrillation

The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals…

Treat Guidel Med Lett. 2010 Sep; 8(97):65-70
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.
Issue 84 · August 1, 2009
Drugs for Thyroid Disorders

Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.

Treat Guidel Med Lett. 2009 Aug; 7(84):57-64
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Issue 77 · January 1, 2009
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs…

Treat Guidel Med Lett. 2009 Jan; 7(77):1-10
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines ( volume 1, page 19, December 2002 ) and in The Medical Letter ( volume 50, page 73, September 22, 2008 ).
Issue 1281 · March 10, 2008
Nebivolol (Bystolic) for Hypertension

Nebivolol ( Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.

Med Lett Drugs Ther. 2008 Mar 10; 50(1281):17-9
Nebivolol ( Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.
Issue 67 · March 1, 2008
Drugs for Migraine

Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve…

Treat Guidel Med Lett. 2008 Mar; 6(67):17-22
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 58 · June 1, 2007
Drugs for Cardiac Arrhythmias

The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.

Treat Guidel Med Lett. 2007 Jun; 5(58):51-8
The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.
Issue 41 · January 1, 2006
Drugs for Treatment of Heart Failure

The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the…

Treat Guidel Med Lett. 2006 Jan; 4(41):1-4
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the incidence of sudden death in patients with heart failure and the treatment of decompensated heart failure were discussed in previous issues.
Issue 1215 · August 15, 2005
AmpliChip CYP450 Test

The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):71-2
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.
Issue 34 · June 1, 2005
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs…

Treat Guidel Med Lett. 2005 Jun; 3(34):39-48
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Issue 1201 · January 31, 2005
Topiramate (Topamax) for Prevention of Migraine

Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent…

Med Lett Drugs Ther. 2005 Jan 31; 47(1201):9-10
Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent years some antiepileptic drugs such as valproate ( Depakote , and others) and topiramate (Topamax) have also been used for this indication. Valproate was approved by the FDA for such use in 1996. Now topiramate has also been approved.
Issue 1195 · November 8, 2004
Tablet Splitting

Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose…

Med Lett Drugs Ther. 2004 Nov 8; 46(1195):89-91
Breaking drug tablets in half is a common practice. In some cases, a lower drug dose may be as effective as a higher one, with fewer adverse effects. Sometimes tablets are split to achieve an intermediate dose between marketed strengths. When 2 tablet sizes cost the same, as they often do, splitting the larger size saves money. Is this a reasonable practice?
Issue 27 · November 1, 2004
Drugs for Cardiac Arrhythmias

The drugs of choice for treatment of common cardiac arrhythmias are listed in the table that begins on the next page; some drugs are recommended for indications for which they have not been approved by the US…

Treat Guidel Med Lett. 2004 Nov; 2(27):75-82
The drugs of choice for treatment of common cardiac arrhythmias are listed in the table that begins on the next page; some drugs are recommended for indications for which they have not been approved by the US FDA. The dosages and adverse effects of each drug are listed in the table that begins on page 80. Antiarrhythmic drugs may themselves cause arrhythmias, which can be fatal. Some of these drugs may increase rather than decrease mortality, especially in patients with structural heart disease.
Issue 1189 · August 16, 2004
Telithromycin (Ketek) for Respiratory Infections

Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in…

Med Lett Drugs Ther. 2004 Aug 16; 46(1189):66-8
Telithromycin ( Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 8 · April 1, 2003
Drugs for Treatment of Heart Failure

The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well…

Treat Guidel Med Lett. 2003 Apr; 1(8):53-6
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as hemodynamic mechanisms. The treatment of decompensated heart failure is not discussed here; drugs used for this indication were reviewed in Cardiovascular Drugs in the ICU, Treatment Guidelines from The Medical Letter 2002; 1:19 .
Issue 6 · February 1, 2003
Drugs for Hypertension

Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs…

Treat Guidel Med Lett. 2003 Feb; 1(6):33-40
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Issue 1099 · March 5, 2001
Drugs for Hypertension

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 2001 Mar 5; 43(1099):17-22
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Issue 1097 · February 5, 2001
Which Beta-Blocker?

Some classes of drugs include so many agents that hospital formulary committees, managed care organizations and individual practitioners may find it difficult to choose among them. Fifteen beta-adrenergic…

Med Lett Drugs Ther. 2001 Feb 5; 43(1097):9-11
Some classes of drugs include so many agents that hospital formulary committees, managed care organizations and individual practitioners may find it difficult to choose among them. Fifteen beta-adrenergic receptor antagonists (beta-blockers) are now marketed for systemic use in the USA. One or more have been approved by the FDA for use in hypertension and eight other indications.
Issue 1091 · October 30, 2000
Colesevelam (Welchol) For Hypercholesterolemia

Colesevelam hydrochloride ( Welchol - Sankyo Pharma), a nonabsorbed hydrophilic polymer that binds bile acids, has been approved by the FDA for reduction of plasma LDL cholesterol in patients with primary…

Med Lett Drugs Ther. 2000 Oct 30; 42(1091):102-4
Colesevelam hydrochloride ( Welchol - Sankyo Pharma), a nonabsorbed hydrophilic polymer that binds bile acids, has been approved by the FDA for reduction of plasma LDL cholesterol in patients with primary hypercholesterolemia.
Issue 1083 · July 24, 2000
Pantroprazole (Protonix)

Pantoprazole, the fourth benzimidazole proton pump inhibitor to become available in the United States, has been marketed for short-term oral treatment of erosive gastroesophageal reflux disease (GERD).

Med Lett Drugs Ther. 2000 Jul 24; 42(1083):65-6
Pantoprazole, the fourth benzimidazole proton pump inhibitor to become available in the United States, has been marketed for short-term oral treatment of erosive gastroesophageal reflux disease (GERD).
Issue 1048 · March 12, 1999
Drugs for Hypertension

Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.

Med Lett Drugs Ther. 1999 Mar 12; 41(1048):23-8
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Issue 1045 · January 29, 1999
Drugs for Chronic Heart Failure

The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.

Med Lett Drugs Ther. 1999 Jan 29; 41(1045):12-4
The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.
Issue 1041 · December 4, 1998
Citalopram for Depression

Citalopram hydrobromide ( Celexa - Forest/Parke-Davis), a selective serotonin reuptake inhibitor (SSRI) available in Europe since 1989, has now been approved by the US Food and Drug Administration (FDA) for…

Med Lett Drugs Ther. 1998 Dec 4; 40(1041):113-4
Citalopram hydrobromide ( Celexa - Forest/Parke-Davis), a selective serotonin reuptake inhibitor (SSRI) available in Europe since 1989, has now been approved by the US Food and Drug Administration (FDA) for treatment of depression. It is being advertised as having a 'favorable side-effect profile.'
Issue 1037 · October 9, 1998
New "Triptans" and Other Drugs for Migraine

Three new 5-HT1 receptors agonissts ('triptans') have been marketed recently for treatment of migraine. Some drugs for prevention of migraine are listed in the table on page 99. Treatment of migraine in the…

Med Lett Drugs Ther. 1998 Oct 9; 40(1037):97-100
Three new 5-HT1 receptors agonissts ('triptans') have been marketed recently for treatment of migraine. Some drugs for prevention of migraine are listed in the table on page 99. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 1010 · September 26, 1997
Carvedilol for Heart Failure

Carvedilol ( Coreg - SmithKline Beecham and Boehringer-Mannheim), a betaadrenergic and alpha-adrenergic blocker approved by the FDA for treatment of hypertension in 1995, but not marketed at that time, has now…

Med Lett Drugs Ther. 1997 Sep 26; 39(1010):89-91
Carvedilol ( Coreg - SmithKline Beecham and Boehringer-Mannheim), a betaadrenergic and alpha-adrenergic blocker approved by the FDA for treatment of hypertension in 1995, but not marketed at that time, has now been approved and marketed for treatment of mild or moderate (NYHA class II or III) heart failure stabilized on other drugs. It is being promoted as an add-on drug that reduces the morbidity and mortality of the disease.
Issue 985 · October 11, 1996
Drugs for Chronic Heart Failure

Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on…

Med Lett Drugs Ther. 1996 Oct 11; 38(985):92-4
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on different mechanisms are commonly used together.
Issue 943 · March 3, 1995
Drugs for Migraine

Drugs are used both to prevent and treat migraine symptoms. The effectiveness of such use can be difficult to evaluate, even with double-blind controlled trials, because migraine is episodic, response to…

Med Lett Drugs Ther. 1995 Mar 3; 37(943):17-20
Drugs are used both to prevent and treat migraine symptoms. The effectiveness of such use can be difficult to evaluate, even with double-blind controlled trials, because migraine is episodic, response to placebo is frequent, and patients vary in response to a given agent (KMA Welch, N Engl J Med, 329:1476, 1993; SD Silberstein and RB Lipton, Neurology, 44 suppl 7:S6, Oct 1994).
Issue 937 · December 9, 1994
Drugs for Stable Angina Pectoris

Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the…

Med Lett Drugs Ther. 1994 Dec 9; 36(937):111-4
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Issue 896 · May 14, 1993
Drugs for Chronic Heart Failure

Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs…

Med Lett Drugs Ther. 1993 May 14; 35(896):40-2
Chronic heart failure results from an iterplay between hemodynamic and neurohormonal factors (M Packer, Lancet, 340:88, 92, 1992). For patients with heart failure due to left ventricular dysfunction, drugs that decrease cardicac preload and afterload and those that increase contractility are commonly used together.
Issue 838 · February 22, 1991
Doxazosin For Treatment of Hypertension

Doxazosin (mesylate - Roerig), an alpha1-adrenergic receptor blocker similar to prazosin ( Minipress , and others) and terazosin ( Hytrin ), was recently approved by the US Food and Drug Administration for…

Med Lett Drugs Ther. 1991 Feb 22; 33(838):15-6
Doxazosin (mesylate - Roerig), an alpha1-adrenergic receptor blocker similar to prazosin ( Minipress , and others) and terazosin ( Hytrin ), was recently approved by the US Food and Drug Administration for treatment of hypertension.
Issue 821 · June 29, 1990
Betaxolol for Hypertension

Betaxolol ( Kerlone - Searle), an oral beta-adrenergic blocker, was recently approved by the US Food and Drug Administration for once-daily treatment of hypertension. The new drug is beta 1 (cardio)-selective…

Med Lett Drugs Ther. 1990 Jun 29; 32(821):61-2
Betaxolol ( Kerlone - Searle), an oral beta-adrenergic blocker, was recently approved by the US Food and Drug Administration for once-daily treatment of hypertension. The new drug is beta 1 (cardio)-selective with no intrinsic sympathomimetic (partial agonist) activity. It is also available in a topical formulation for treatment of glaucoma ( Betoptic - Medical Letter, 28:45, 1986). Beta-blockers currently available in the USA for treatment of hypertension are listed in the table below.
Issue 797 · July 28, 1989
Carteolol and Penbutolol For Hypertension

Carteolol ( Cartrol - Abbott) and penbutolol ( Levatol - Reed & Carnrick), two oral beta-adrenergic blocking drugs, were recently approved by the US Food and Drug Administration for once-daily treatment of…

Med Lett Drugs Ther. 1989 Jul 28; 31(797):70-1
Carteolol ( Cartrol - Abbott) and penbutolol ( Levatol - Reed & Carnrick), two oral beta-adrenergic blocking drugs, were recently approved by the US Food and Drug Administration for once-daily treatment of systemic hypertension. Both drugs are non-selective beta-blockers with mild partial agonist activity. Beta-blockers currently available in the USA for treatment of hypertension are listed in the table on the next page.
Issue 763 · April 8, 1988
Lisinopril For Hypertension

- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors,…

Med Lett Drugs Ther. 1988 Apr 8; 30(763):41-2
- Merck; Zestril - Stuart), a new angiotensin-converting enzyme (ACE) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for once-daily treatment of . Two other ACE inhibitors, captopril ( Capoten - Squibb) and e